UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 7.303

Sortiert nach

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients

Journal of the European Academy of Dermatology and Venereology, 2020-03, Vol.34 (3), p.533-541

2020

Link zum Volltext

Verfügbarkeit prüfen

Comparison of ixekizumab with ustekinumab in moderate‐to‐severe psoriasis: 24‐week results from IXORA‐S, a phase III study

British journal of dermatology (1951), 2017-10, Vol.177 (4), p.1014-1023

2017

Link zum Volltext

Verfügbarkeit prüfen

Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker - a retrospective multicenter study

The Journal of dermatological treatment, 2021-12, Vol.32 (8), p.878-882

2021

Link zum Volltext

Verfügbarkeit prüfen

Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity

British journal of dermatology (1951), 2017-11, Vol.177 (5), p.1401-1409

2017

Link zum Volltext

Verfügbarkeit prüfen

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial

British journal of dermatology (1951), 2021-06, Vol.184 (6), p.1047-1058

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of ixekizumab in a phase III, randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)

British journal of dermatology (1951), 2020-08, Vol.183 (2), p.231-241

2020

Link zum Volltext

Verfügbarkeit prüfen

Adiponectin levels in a large pooled plaque psoriasis study population

The Journal of dermatological treatment, 2020-07, Vol.31 (5), p.531-534

2020

Link zum Volltext

Verfügbarkeit prüfen

Endocannabinoid analysis in GlucoEXACT plasma: Method validation and sample handling recommendations

Talanta (Oxford), 2024-10, Vol.278, p.126518, Article 126518

2024

Link zum Volltext

Verfügbarkeit prüfen

比较生物制剂依奇珠单抗与其他两种治疗银屑病的药物富马酸酯和甲氨蝶呤的试验

British journal of dermatology (1951), 2020-04, Vol.182 (4), p.e148-e148

2020

Link zum Volltext

Verfügbarkeit prüfen

A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, 2022-02, Vol.36 (2), p.228-236

2022

Link zum Volltext

Verfügbarkeit prüfen

Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate‐to‐severe plaque psoriasis: a randomized controlled trial

British journal of dermatology (1951), 2022-01, Vol.186 (1), p.30-39

2022

Link zum Volltext

Verfügbarkeit prüfen

A novel calcipotriol and betamethasone dipropionate (CAL/BDP) PAD‐cream demonstrates greater improvements in daily activities and personal relationships than CAL/BDP gel/TS: A post‐hoc analysis of DLQI outcomes from two phase 3 placebo‐controlled randomized clinical trials in mild‐to‐moderate psoriasis

Journal of the European Academy of Dermatology and Venereology, 2024-04, Vol.38 (4), p.e326-e328

2024

Link zum Volltext

Verfügbarkeit prüfen

A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment

British journal of dermatology (1951), 2020-04, Vol.182 (4), p.869-879

2020

Link zum Volltext

Verfügbarkeit prüfen

Randomised Phase 3 trial demonstrating high efficacy, favourable safety, and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis

Journal of the European Academy of Dermatology and Venereology, 2023-11, Vol.37 (11), p.2327-2335

2023

Link zum Volltext

Verfügbarkeit prüfen

Land‐use change and the ecological consequences of personality in small mammals

Ecology letters, 2019-09, Vol.22 (9), p.1387-1395

2019

Link zum Volltext

Verfügbarkeit prüfen

Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS)

British journal of dermatology (1951), 2020-08, Vol.183 (2), p.265-275

2020

Link zum Volltext

Verfügbarkeit prüfen

Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study

Journal of the European Academy of Dermatology and Venereology, 2023-10, Vol.37 (10), p.2016-2027

2023

Link zum Volltext

Verfügbarkeit prüfen

苏金单抗持续用于治疗银屑病的疗效

British journal of dermatology (1951), 2020-01, Vol.182 (1), p.e39-e39

2020

Link zum Volltext

Verfügbarkeit prüfen

Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study

Journal of the European Academy of Dermatology and Venereology, 2021-07, Vol.35 (7), p.1562-1568

2021

Link zum Volltext

Verfügbarkeit prüfen

Spatial personalities: a meta-analysis of consistent individual differences in spatial behavior

Behavioral ecology, 2022-05, Vol.33 (3), p.477-486

2022

Link zum Volltext

Verfügbarkeit prüfen

Metabolomic and lipidomic fingerprints in inflammatory skin diseases – Systemic illumination of atopic dermatitis, hidradenitis suppurativa and plaque psoriasis

Clinical immunology (Orlando, Fla.), 2024-08, Vol.265, p.110305, Article 110305

2024

Link zum Volltext

Verfügbarkeit prüfen

Cooperative breeding and the emergence of multilevel societies in birds

Ecology letters, 2022-04, Vol.25 (4), p.766-777

2022

Link zum Volltext

Verfügbarkeit prüfen

Speed of clinical improvement in the real‐world setting from patient‐reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks

Journal of the European Academy of Dermatology and Venereology, 2023-09, Vol.37 (9), p.1825-1840

2023

Link zum Volltext

Verfügbarkeit prüfen

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, 2022-06, Vol.36 (6), p.855-865

2022

Link zum Volltext

Verfügbarkeit prüfen

Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study

British journal of dermatology (1951), 2019-12, Vol.181 (6), p.1177-1189

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 7.303

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(5.736)
Mit Volltextzugriff
(6.232)

Publikationsform

8 weitere anzeigen...

Weniger anzeigen...

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(3.441)
Life Sciences & Biomedicine
(2.246)
Humans
(1.550)
Female
(916)
Male
(877)
Physical Sciences
(860)
Animals
(702)
Technology
(641)
Biological And Medical Sciences
(593)
Middle Aged
(451)
Adult
(433)
Aged
(356)
Chemistry
(342)
Neurosciences & Neurology
(323)
Fundamental And Applied Biological Sciences. Psychology
(314)
Medical Sciences
(306)
Engineering
(281)
Exact Sciences And Technology
(257)
Physics
(239)
Neurosciences
(220)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Orvosi Hetilap
(218)
Journal Of Pediatric Surgery
(114)
Journal Of Hepatology
(98)
Plos One
(58)
Journal Of Clinical Oncology
(54)
Physics Letters. B
(52)
Journal Of Virology
(44)
Blood
(43)
Agricultural And Forest Meteorology
(41)
Cheminform
(39)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients

Comparison of ixekizumab with ustekinumab in moderate‐to‐severe psoriasis: 24‐week results from IXORA‐S, a phase III study

Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker - a retrospective multicenter study

Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial

Efficacy and safety of ixekizumab in a phase III, randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)

Adiponectin levels in a large pooled plaque psoriasis study population

Endocannabinoid analysis in GlucoEXACT plasma: Method validation and sample handling recommendations

比较生物制剂依奇珠单抗与其他两种治疗银屑病的药物富马酸酯和甲氨蝶呤的试验

A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis

Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate‐to‐severe plaque psoriasis: a randomized controlled trial

A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment

Randomised Phase 3 trial demonstrating high efficacy, favourable safety, and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis

Land‐use change and the ecological consequences of personality in small mammals

Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS)

Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study

苏金单抗持续用于治疗银屑病的疗效

Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study

Spatial personalities: a meta-analysis of consistent individual differences in spatial behavior

Metabolomic and lipidomic fingerprints in inflammatory skin diseases – Systemic illumination of atopic dermatitis, hidradenitis suppurativa and plaque psoriasis

Cooperative breeding and the emergence of multilevel societies in birds

Speed of clinical improvement in the real‐world setting from patient‐reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis

Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study

Suchergebnisse filtern